CuraFi Header Image


Xolair for Treatment of Severe Asthma

Vishal Banthia, MD FACS Feb 22, 2023

Xolair is a revolutionary new therapy that has been approved by the FDA to treat moderate-to-severe asthma and chronic hives. It is a monoclonal antibody (mAb) that targets and neutralizes immunoglobulin E (IgE), a type of protein involved in allergic reactions. Xolair works by binding to IgE and preventing it from binding to other proteins that can trigger an allergic reaction.

The clinical trials conducted on Xolair have shown that it is an effective treatment for both asthma and chronic hives. In clinical trials, Xolair has been proven to reduce asthma symptoms, improve quality of life, and reduce the need for rescue medications. Xolair is also used to treat chronic hives, a condition that causes intensely itchy skin rashes. In clinical trials, Xolair has been proven to reduce the severity of hives and improve quality of life.

Xolair is administered as an injection every two to four weeks at a doctor's office. It is available in both a single-dose vial and a multi-dose vial, which is more cost-effective for patients.